CN105833109B - Moringa oleifera-containing composition for treating hyperglycemia and hyperlipidemia and preparation method and application thereof - Google Patents
Moringa oleifera-containing composition for treating hyperglycemia and hyperlipidemia and preparation method and application thereof Download PDFInfo
- Publication number
- CN105833109B CN105833109B CN201610421585.3A CN201610421585A CN105833109B CN 105833109 B CN105833109 B CN 105833109B CN 201610421585 A CN201610421585 A CN 201610421585A CN 105833109 B CN105833109 B CN 105833109B
- Authority
- CN
- China
- Prior art keywords
- moringa oleifera
- volatile oil
- hyperlipidemia
- composition
- oleifera
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000179886 Moringa oleifera Species 0.000 title claims abstract description 111
- 235000011347 Moringa oleifera Nutrition 0.000 title claims abstract description 111
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 30
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000341 volatile oil Substances 0.000 claims abstract description 44
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 6
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 5
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 5
- 229960004853 betadex Drugs 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 13
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 235000014676 Phragmites communis Nutrition 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 241000405414 Rehmannia Species 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 241000045403 Astragalus propinquus Species 0.000 claims description 5
- 235000006533 astragalus Nutrition 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000001256 steam distillation Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 42
- 210000004369 blood Anatomy 0.000 abstract description 41
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 20
- 230000001603 reducing effect Effects 0.000 abstract description 20
- 238000010791 quenching Methods 0.000 abstract description 8
- 238000010926 purge Methods 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 230000002787 reinforcement Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010020710 Hyperphagia Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000014590 basal diet Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 208000022530 polyphagia Diseases 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000143687 Cantua buxifolia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000380450 Danaus melanippus Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000005985 stomach dysfunction Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
The invention relates to a composition containing moringa oleifera for treating hyperglycemia and hyperlipidemia, the formula follows the traditional theory of traditional Chinese medicine for treating diabetes and hyperlipidemia by clearing heat and purging fire, the composition containing moringa oleifera for treating hyperglycemia and hyperlipidemia is provided, all components of the composition are in mutual reinforcement and mutual assistance, the composition has the effects of obviously improving the effects of reducing blood sugar and reducing blood fat, the moringa oleifera volatile oil components are reserved, the moringa oleifera volatile oil is solidified by a beta-cyclodextrin inclusion technology, the effects of reducing blood sugar and reducing blood fat are superior to those of a classic formula, namely a thirst-quenching formula, the preparation process is simple, and the composition is suitable for industrial production.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines or health-care products, and particularly relates to a traditional Chinese medicine composition, in particular to a moringa oleifera-containing composition for treating hyperglycemia and hyperlipidemia, and a preparation method and application thereof.
Background
With the improvement of daily living standard of people, the incidence of diabetes and hyperlipidemia is on the trend of rising year by year, and both diseases belong to chronic diseases, are difficult to treat, can generate various complications in a progressive manner, and seriously affect the life quality of people.
Diabetes is metabolic disorder characterized by chronic hyperglycemia caused by various reasons, the hyperglycemia is taken as a main characteristic clinically, common symptoms comprise polyuria, polydipsia, polyphagia, emaciation and the like, the diabetes belongs to the category of diabetes in traditional Chinese medicine, the traditional Chinese medicine has been recorded in Huangdi's internal classic, the traditional Chinese medicine has been recorded in LingShu & Wuchang's article, the five organs are all weak, the principal symptoms and pathogenic reasons of diabetes are good for fever and diabetes, the traditional Chinese medicine has the pathogenesis of lung dysfunction, the traditional Chinese medicine has the pathogenesis of spleen and stomach dysfunction and the traditional Chinese medicine has the pathogenesis of kidney dysfunction in the white tiger plus ginseng decoction for treating diabetes in the Shanghai's Wen Gu miscellaneous disease treatise for thousands of years, in the traditional Chinese medicine, the diabetes is caused by yin deficiency, congenital endowment deficiency, improper diet, overeating fatness, emotional disorder and excessive desire, the treatment of the diabetes needs to treat both symptoms and root causes, and the disease roots are eliminated in a mode of dialectical treatment by adopting treatment methods of clearing heat and purging fire, tonifying spleen and kidney and the like. Aiming at diabetes, a series of traditional Chinese medicine classic formulas exist, such as Baihu decoction, stomach-regulating qi-supporting decoction, Zhongwan pill, dark plum pill, six-position decoction, honey-fried licorice decoction, diabetes-treating formula and Yuquan powder, wherein the diabetes-treating formula is especially known as the diabetes-treating formula, the Yuquan powder and the Baihu decoction, wherein the diabetes-treating formula is originated from Zhudanxi which is one of Jinyuan four main people, and is prepared from coptis root powder, smallpox powder, human milk (or cow milk), lotus root juice, rehmannia root juice, ginger juice and honey which are stirred together to form paste for oral administration, and mainly treats the symptoms of diabetes, such as easy hunger, polyphagia, thirst, polydipsia and the like. Yuquan powder is originated by leaf Tianshi of famous warm disease doctors in Ming and Qing provinces, is composed of radix puerariae powder, radix trichosanthis, radix ophiopogonis, rehmannia glutinosa, sticky rice, schisandra chinensis and liquorice, can clear heat and purge fire, and is used for treating symptoms such as yang Ming interior heat, polydipsia and headache.
Hyperlipemia is one of the common diseases in modern cities, and the symptoms of high cholesterol content or high triglyceride content in human blood or high cholesterol content and triglyceride content in human blood are called hyperlipemia, namely hyperlipidemia, which is caused by overeating greasy food, irregular biology, lack of exercise and the like. The disease name of hyperlipemia does not exist in the theory of traditional Chinese medicine, the clinical manifestation of hyperlipemia is observed, and the ancient medicine is described by the words of phlegm dampness, blood turbidity, obesity, damp-heat and the like for household, and the symptoms belong to the category of 'leukemia' (also called as lipid turbidity disease) in the clinical practice of traditional Chinese medicine. The traditional Chinese medicine considers that the formation, transformation and metabolism of grease in human blood are influenced by viscera such as spleen, stomach, liver, kidney, large intestine and the like, wherein the viscera such as spleen, liver, kidney and the like have the greatest influence on the formation of the grease. If the spleen qi is insufficient, the transportation and transformation functions are affected, which results in endogenous dampness, transformation of phlegm to obstruct channels and collaterals, stagnation of liver qi, hyperactivity of liver yang, impaired spleen and stomach function, abnormal transportation and transformation, and phlegm retention and heat accumulation of dampness, which results in abnormal transportation of food essence and accumulation of food essence in the body.
Moringa (Moringa), also called drumstick tree, tree with fallen leaves in tropical zone of many years, northern India, China also has a large amount of plants, which are mainly used as ornamental trees and also have certain economic value, and seeds can purify water and produce edible oil. The leaves and the fruit pods of the moringa oleifera are rich in various minerals, vitamins and 20 amino acids, and research shows that the content of vitamin E in each 100 g of fresh leaves of the moringa oleifera is about 9 mg, the content of vitamin C in each 100 g of the moringa oleifera is about 16.2 mg, and the content of vitamin C in each 100 g of the moringa oleifera is 7 times that of citrus. Therefore, the moringa oleifera can be used as vegetables, medicinal materials and food, is widely applied to nutrition enhancement, food therapy health care and medical health preservation, is known as a magic tree, can enhance immunity, is beneficial to regulating blood sugar, reducing cholesterol, resisting oxidation and free radicals and eliminating active oxygen of a human body, has obvious effects of reducing blood pressure, blood fat and blood sugar after being taken for a long time, and can also prevent cancer, enhance digestion, nourish spleen and stomach, eliminate fatigue, balance skin pigment, inhibit bacteria, expel parasites and the like.
For the effective active substances of the moringa oleifera for reducing blood sugar, the moringa oleifera is generally considered to be flavonoid with the effects of resisting oxidation and removing free radicals, so that the flavonoid extract of the moringa oleifera is mostly adopted to prepare blood sugar-reducing health-care products or medicines, and for the moringa oleifera volatile oil, the high oxidation resistance of the moringa oleifera volatile oil is mostly utilized to develop cosmetics and the like.
Disclosure of Invention
Under the guidance of the traditional Chinese medicine theory, the invention provides a composition containing moringa oleifera for treating hyperglycemia and hyperlipidemia by taking heat clearing and fire purging as a formula principle, and is characterized in that: is prepared from 5-10 parts of moringa oleifera, 3-5 parts of radix rehmanniae recen, 5-8 parts of astragalus membranaceus and 2-4 parts of reed rhizome.
Preferably, the composition containing moringa oleifera for treating hyperglycemia and hyperlipidemia is prepared from 10 parts of moringa oleifera, 5 parts of radix rehmanniae recen, 6 parts of astragalus membranaceus and 4 parts of reed rhizome as raw material medicines.
More preferably, the composition comprises moringa oleifera volatile oil.
Further, the invention also provides a preparation method of the composition containing moringa oleifera for treating hyperglycemia and hyperlipidemia, which comprises the following steps:
(1) smashing and extracting moringa oleifera: pulverizing Moringa oleifera to 80-100 meshes to obtain Moringa oleifera powder, extracting Moringa oleifera volatile oil from the Moringa oleifera powder by steam distillation to obtain Moringa oleifera volatile oil, Moringa oleifera water distillate and Moringa oleifera residue;
(2) mixing and extracting: squeezing radix rehmanniae and rhizoma Phragmitis together to obtain radix rehmanniae rhizoma Phragmitis juice and radix rehmanniae rhizoma Phragmitis residue, pulverizing radix astragali to 80-100 mesh to obtain radix astragali powder, mixing Moringa oleifera residue, radix rehmanniae rhizoma Phragmitis residue and radix astragali powder, adding 8-10 times of distilled water, extracting for 2-3 times (each time for 1-2 hr), filtering, mixing filtrate and Moringa oleifera water distillate, and concentrating to obtain mixed extract with relative density of 1.05-1.25 at 60 deg.C;
(3) and (3) inclusion of the moringa oleifera volatile oil with dextrin: the moringa oleifera volatile oil is included by beta-cyclodextrin with the weight 6-10 times of that of the moringa oleifera volatile oil, and the moringa oleifera volatile oil inclusion compound is obtained after drying:
(4) mixing: and mixing the mixed extract, the raw rehmannia root reed rhizome juice and the moringa oleifera volatile oil inclusion compound, and uniformly stirring to obtain the composition containing the moringa oleifera for treating hyperglycemia and hyperlipidemia.
The composition for treating hyperglycemia and hyperlipidemia, which comprises moringa oleifera of the present invention, can be further used as a food additive, a health product or a medicine, and when the composition is used as a health product or a medicine, suitable dosage forms of the composition include, but are not limited to: tablets, capsules, granules, solutions and the like.
Further, the tablet is a sugar-coated tablet, and the capsule is a soft capsule or a hard capsule.
The invention has the beneficial effects that:
(1) the invention follows the traditional treatment rules of clearing heat and purging fire in traditional Chinese medicine to treat diabetes and reduce blood fat, and provides a composition containing moringa oleifera for treating hyperglycemia and hyperlipidemia through a reasonable formula, wherein the components of the composition are mutually reinforced and matched, so that the composition has the effects of obviously improving the effects of reducing blood sugar and blood fat;
(2) the moringa oleifera volatile oil is used for treating diabetes and hyperlipidemia for the first time, and has an obviously better treatment effect compared with a composition only adopting a moringa oleifera aqueous extract;
(3) the moringa oleifera volatile oil is solidified by adopting a cyclodextrin inclusion technology, so that the loss of the moringa oleifera volatile oil is avoided, and the dosage form types of the composition are increased;
(4) the composition of the invention has simple preparation method and is suitable for industrial production.
Detailed description of the preferred embodiments
The following examples are intended to illustrate the invention without further limiting it, which can be carried out in any of the ways described in the summary of the invention.
Example 1: composition containing moringa oleifera for treating hyperglycemia and hyperlipidemia
10 parts of moringa oleifera, 5 parts of radix rehmanniae recen, 6 parts of astragalus membranaceus and 4 parts of reed rhizome;
is prepared by the following steps:
(1) smashing and extracting moringa oleifera: pulverizing Moringa oleifera to 100 meshes to obtain Moringa oleifera powder, extracting Moringa oleifera volatile oil from the Moringa oleifera powder by steam distillation to obtain Moringa oleifera volatile oil, Moringa oleifera water distillate and Moringa oleifera residue;
(2) mixing and extracting: squeezing radix rehmanniae and rhizoma Phragmitis together to obtain radix rehmanniae rhizoma Phragmitis juice and radix rehmanniae rhizoma Phragmitis residue, pulverizing radix astragali to 100 mesh to obtain radix astragali powder, mixing Moringa oleifera residue, radix rehmanniae rhizoma Phragmitis residue and radix astragali powder, adding 10 times of distilled water for 2 times (1 hr each time), filtering, mixing the filtrate and Moringa oleifera water distillate, and concentrating to obtain mixed extract with relative density of 1.05-1.25 at 60 deg.C;
(3) and (3) inclusion of the moringa oleifera volatile oil with dextrin: the moringa oleifera volatile oil is included by beta-cyclodextrin with the weight 8 times of that of the moringa oleifera volatile oil, and the moringa oleifera volatile oil inclusion compound is obtained after drying:
(4) mixing: and mixing the mixed extract, the raw rehmannia root reed rhizome juice and the moringa oleifera volatile oil inclusion compound, and uniformly stirring to obtain the composition containing the moringa oleifera for treating hyperglycemia and hyperlipidemia.
Comparative example 1: composition without moringa oleifera volatile oil
The other steps are the same as the example 1, and only in the step (4), the moringa oleifera volatile oil is not added, so that the composition without the moringa oleifera volatile oil is obtained.
Effect example 1: experiment of blood sugar lowering Effect
1. Experimental materials:
1.1 Experimental animals: the weight of Kunming male mice is 19-22 g.
1.2 test drugs: (1) the composition of example 1; (2) comparative example 1 composition; (3) the thirst quenching formula comprises a high dose group and a low dose group, wherein the high dose group is used for performing intragastric gavage according to 1g crude drug/Kg body weight, and the low dose group is used for performing intragastric gavage according to 0.5g crude drug/Kg, and each intragastric gavage is 1 mL.
2. Experimental methods
2.1, molding: and (3) carrying out molding on Kunming male mice with the weight of 19-22 g by intraperitoneal injection of streptozotocin at the weight of 150mg/Kg, measuring the blood sugar value of the mice after 72 hours, and selecting 60 mice with the blood sugar value of 15-25mmol/L after molding for subsequent experiments.
2.2 hypoglycemic experiments: the selected 60 mice are randomly divided into a negative control group, a high dose group of example 1, a low dose group of example 1, a high dose group of comparative example 1, a low dose group of comparative example 1 and a thirst-eliminating group, the gavage administration is carried out for 1 time per day, wherein, the gavage of the negative control group is carried out with distilled water with the same amount, the blood sugar value of each group of mice is measured after 7 days of the administration, the blood sugar reduction rate is calculated,
wherein the blood glucose lowering rate is (blood glucose value before administration-blood glucose value after administration)/blood glucose value before administration x 100%
Specific results are shown in table 1:
TABLE 1 blood glucose in mice
Note: p < 0.05, P < 0.01, compared to the negative control group.
The experimental results in Table 1 show that the thirst-quenching drug has a higher blood sugar reduction rate than the negative control group, and shows that the thirst-quenching drug has an obvious effect of reducing the blood sugar of mice, the composition in the embodiment 1 of the invention has the blood sugar reducing effect which is obviously superior to that of the diabetes mellitus under the dosage of 1g crude drug/Kg body weight and 0.5g crude drug/Kg body weight, and has certain dose dependent effect, while the high-dose group and the low-dose group of the comparative document 1 containing no moringa oleifera volatile oil show comparable blood sugar lowering effects, the blood sugar lowering effects are obviously inferior to those of the group of example 1 containing moringa oleifera volatile oil, the blood sugar reducing effect of the high-dose group in the comparative example 1 is still worse than that of the low-dose group in the example 1, which shows that the composition has obviously improved blood sugar reducing effect after the moringa volatile oil is added, so that the moringa-containing composition with better blood sugar reducing effect is provided.
Effect example 2: blood lipid lowering effect experiment
1. Experimental materials:
1.1 Experimental animals: the weight of Kunming male mice is 19-22 g.
1.2 test drugs: (1) example 1 composition high and low dose groups; (2) comparative example 1 high and low dose groups of composition; (3) the diabetes treating group comprises a high dose group and a low dose group, wherein the high dose group is used for performing intragastric administration according to 1g crude drug/Kg body weight, and the low dose group is used for performing intragastric administration according to 0.5g crude drug/Kg, and the intragastric administration is performed by 1mL each time.
2 method of experiment
70 male Kunming mice with the weight of 19-22 g are randomly divided into 7 groups: a normal group, a negative control group, an example 1 high dose group, an example 1 low dose group, a comparative example 1 high dose group, a comparative example 1 low dose group and a thirst quenching group, wherein the normal group is fed with basal diet, the remaining 6 groups are fed with high fat diet (80% basal diet, 1.5% cholesterol, 8.5% egg yolk powder, 10% lard), the experimental drug is simultaneously gazed, the negative control group is gazed with distilled water in equal amount for 1 time a day, after 30 days of administration, the orbit of each group of mice is bled, and the serum TC and TG of the mice are measured, and the specific results are shown in table 2:
TABLE 2 mouse blood lipid changes
Note: p < 0.05, P < 0.01, compared to the negative control group.
The experimental results in table 2 show that the thirst-quenching formula has the effect of reducing serum total cholesterol and serum triglyceride of high-fat-fed mice, while the high dose of the composition in example 1 has very obvious serum total cholesterol and serum triglyceride reducing effect, and the corresponding effect of the low dose group of the composition in example 1 is still better than that of the thirst-quenching formula group, which indicates that the composition containing moringa oleifera of the present invention has excellent blood fat reducing effect and dose-dependent effect. The group of comparative example 1 with high and low doses containing no moringa oleifera volatile oil also showed a certain effect of reducing serum total cholesterol and serum triglyceride, but the effect is significantly weaker than that of the group of example 1 containing moringa oleifera volatile oil, which indicates that the blood lipid reducing effect of the composition can be significantly enhanced after the moringa oleifera volatile oil is introduced into the composition.
Preparation example 1: granule containing Moringa oleifera for treating hyperglycemia and hyperlipidemia
The preparation method comprises the steps of preparing a mixed extract, raw rehmannia reed rhizome juice and a moringa oleifera volatile oil inclusion compound according to the step of the embodiment 1, uniformly mixing the mixed extract and the raw rehmannia reed rhizome juice, drying, crushing, sieving by a 100-mesh sieve, adding the moringa oleifera volatile oil inclusion compound and lactose which is 4 times of the total weight of the composition, uniformly mixing, performing wet granulation, sieving and finishing granules to obtain the granules containing the moringa oleifera and used for treating hyperglycemia and hyperlipidemia.
Preparation example 2: capsule containing Moringa oleifera for treating hyperglycemia and hyperlipidemia
Adding a proper amount of micropowder silica gel into the granules containing moringa oleifera obtained in the preparation example 1 and treating hyperglycemia and hyperlipidemia, uniformly mixing, and filling into a gelatin capsule shell to obtain the capsule containing moringa oleifera and treating hyperglycemia and hyperlipidemia.
Preparation example 3: tablet containing Moringa oleifera for treating hyperglycemia and hyperlipidemia
The preparation method comprises the steps of preparing a mixed extract, raw rehmannia reed rhizome juice and a moringa oleifera volatile oil inclusion compound according to the step of the embodiment 1, uniformly mixing the mixed extract and the raw rehmannia reed rhizome juice, drying, crushing, sieving by a 40-mesh sieve, adding the moringa oleifera volatile oil inclusion compound, microcrystalline cellulose which is 4 times of the weight of the composition, and a mixture of croscarmellose sodium and sodium carboxymethyl starch which is 20% of the weight of the composition, uniformly mixing, performing wet granulation, sieving, granulating, adding a proper amount of magnesium stearate, and tabletting to obtain the tablet containing the moringa for treating hyperglycemia and hyperlipidemia.
Conclusion
Under the guidance of the traditional theory of clearing heat and purging fire in traditional Chinese medicine for treating diabetes and hyperlipidemia, the invention provides the composition containing moringa oleifera for treating hyperglycemia and hyperlipidemia, reserves moringa oleifera volatile oil components, and solidifies the moringa oleifera volatile oil through a beta-cyclodextrin inclusion technology, so that the composition containing moringa oleifera for treating hyperglycemia and hyperlipidemia with obvious effects of reducing blood sugar and blood lipid is obtained, the effects of reducing blood sugar and blood lipid are superior to those of a classic formula, namely a thirst-quenching formula, and the preparation process is simple and is suitable for industrial production.
The examples and preparation examples described in the present invention are only exemplary, and all the compositions for treating hyperglycemia and hyperlipidemia, which comprise moringa oleifera, radix rehmanniae, astragalus membranaceus and rhizoma phragmitis, and the preparation method and use thereof fall within the protection scope of the present invention.
Claims (1)
1. A preparation method of a composition containing moringa oleifera for treating hyperglycemia and hyperlipidemia is characterized in that the composition is prepared from 10 parts of moringa oleifera, 5 parts of radix rehmanniae recen, 6 parts of astragalus membranaceus and 4 parts of reed rhizome as raw material medicines, and the preparation method comprises the following steps:
(1) smashing and extracting moringa oleifera: pulverizing Moringa oleifera to 80-100 meshes to obtain Moringa oleifera powder, extracting Moringa oleifera volatile oil from the Moringa oleifera powder by steam distillation to obtain Moringa oleifera volatile oil, Moringa oleifera water distillate and Moringa oleifera residue;
(2) mixing and extracting: squeezing radix rehmanniae and rhizoma Phragmitis together to obtain radix rehmanniae rhizoma Phragmitis juice and radix rehmanniae rhizoma Phragmitis residue, pulverizing radix astragali to 80-100 mesh to obtain radix astragali powder, mixing Moringa oleifera residue, radix rehmanniae rhizoma Phragmitis residue and radix astragali powder, adding 8-10 times of distilled water, extracting for 2-3 times (each time for 1-2 hr), filtering, mixing filtrate and Moringa oleifera water distillate, and concentrating to obtain mixed extract with relative density of 1.05-1.25 at 60 deg.C;
(3) and (3) inclusion of the moringa oleifera volatile oil with dextrin: the moringa oleifera volatile oil is included by beta-cyclodextrin with the weight 6-10 times of that of the moringa oleifera volatile oil, and the moringa oleifera volatile oil inclusion compound is obtained after drying:
(4) mixing: and mixing the mixed extract, the raw rehmannia root reed rhizome juice and the moringa oleifera volatile oil inclusion compound, and uniformly stirring to obtain the composition containing the moringa oleifera for treating hyperglycemia and hyperlipidemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610421585.3A CN105833109B (en) | 2016-06-15 | 2016-06-15 | Moringa oleifera-containing composition for treating hyperglycemia and hyperlipidemia and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610421585.3A CN105833109B (en) | 2016-06-15 | 2016-06-15 | Moringa oleifera-containing composition for treating hyperglycemia and hyperlipidemia and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105833109A CN105833109A (en) | 2016-08-10 |
| CN105833109B true CN105833109B (en) | 2020-01-17 |
Family
ID=56576185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610421585.3A Active CN105833109B (en) | 2016-06-15 | 2016-06-15 | Moringa oleifera-containing composition for treating hyperglycemia and hyperlipidemia and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105833109B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105124347A (en) * | 2015-07-24 | 2015-12-09 | 海南木辣达生物科技有限公司 | Moringa oleifera blood-glucose-reducing composition and preparation method thereof |
| CN105362674A (en) * | 2015-12-16 | 2016-03-02 | 济南舜祥医药科技有限公司 | Traditional Chinese medicine used for treating diabetes and preparation method thereof |
| CN105381154A (en) * | 2015-12-16 | 2016-03-09 | 顾海峰 | Pharmaceutical composition containing moringa oleifera and preparation method of preparation of pharmaceutical composition |
-
2016
- 2016-06-15 CN CN201610421585.3A patent/CN105833109B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105124347A (en) * | 2015-07-24 | 2015-12-09 | 海南木辣达生物科技有限公司 | Moringa oleifera blood-glucose-reducing composition and preparation method thereof |
| CN105362674A (en) * | 2015-12-16 | 2016-03-02 | 济南舜祥医药科技有限公司 | Traditional Chinese medicine used for treating diabetes and preparation method thereof |
| CN105381154A (en) * | 2015-12-16 | 2016-03-09 | 顾海峰 | Pharmaceutical composition containing moringa oleifera and preparation method of preparation of pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105833109A (en) | 2016-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meireles et al. | A review of properties, nutritional and pharmaceutical applications of Moringa oleifera: integrative approach on conventional and traditional Asian medicine | |
| KR100864455B1 (en) | A Composition comprising the extract of complex herb improving Liver Cirrhosis, cytotoxicity and liver injury for preventing and treating of liver disease | |
| JP2023538664A (en) | Compositions of ginsenoside Rg3 and ginsenoside Rg5 and their pharmaceutical uses, including antitumor effects | |
| KR101627837B1 (en) | Health supplement food comprising horse bone extracts as main ingredients and sea horse and manufacturing method for the same | |
| CN101711840B (en) | Medicine-food dual-purpose composition suitable for cancerous patients and preparation method thereof | |
| KR20160000695A (en) | Herbal-medicine containing dha for recovering fatigue and enhancing memory, and method of manufacturing the same | |
| CN106509894A (en) | Moringa oleifera and pseudo-ginseng buccal tablets and preparation technology thereof | |
| CN108066384A (en) | A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof | |
| CN105833109B (en) | Moringa oleifera-containing composition for treating hyperglycemia and hyperlipidemia and preparation method and application thereof | |
| CN109010579A (en) | A kind of antioxidant and anti-aging Chinese traditional compound medicine and preparation method thereof | |
| CN111616357B (en) | GABA spleen-tonifying and nerve-soothing composition based on homology of medicine and food, preparation and application thereof | |
| CN102000250B (en) | Black-bone chicken health-care medicament as well as preparation method and applications thereof | |
| CN104474099A (en) | Strigose hydrangea leaf cough-relieving syrup and preparation method thereof | |
| KR101783549B1 (en) | Health supplement food containing dha for recovering fatigue, and method of manufacturing the same | |
| CN101745042B (en) | Composition with effects of relieving alcoholism and protecting liver and preparation method thereof | |
| CN107375509A (en) | It is a kind of to be used to improve immunity, the health food of pre- anti-cancer | |
| CN103463456A (en) | Traditional Chinese medicine composition and preparation method thereof | |
| KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
| CN107648335B (en) | Traditional Chinese medicine composition for regulating atherosclerosis autophagy and apoptosis and preparation method thereof | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN108478701A (en) | A kind of lozenge of strengthen immunity | |
| CN110025011A (en) | A kind of Radix Ophiopogonis ginseng lozenge of strengthen immunity | |
| CN103585509A (en) | Compound collina traditional Chinese medicine oral liquid and preparation method thereof | |
| CN109984342B (en) | Medicated diet and preparation method thereof | |
| CN104435359B (en) | A kind of protect liver stichopus japonicus traditional Chinese medicine oral liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20191029 Address after: 050073 No. 598 Heping West Road, Shijiazhuang City, Hebei Province Applicant after: Hebei Academy of Agriculture and Forestry Science, Economic Crops Institute Address before: 050051 Hebei Shijiazhuang Agricultural Sciences Research Center of Agricultural Sciences Applicant before: Xie Xiaoliang |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220525 Address after: 050000 courtyard, No. 88, Hongqi South Street, nanxingguo Township, Zanhuang County, Shijiazhuang City, Hebei Province Patentee after: Hebei Kangping Health Industry Co.,Ltd. Address before: 050073 No. 598, Heping West Road, Shijiazhuang City, Hebei Province Patentee before: INSTITUTE OF CASH CROPS, HEBEI ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES |